ISCO— International Stem Cell CORP

Metric	FY2025	FY2024	FY2023	FY2022
Product sales	$9.1M+0.2%	$9.1M+16.6%	$7.8M-4.8%	$8.2M
Cost of sales	$4.0M+7.1%	$3.8M+18.3%	$3.2M-2.7%	$3.3M
General and administrative	$3.5M+0.5%	$3.5M+0.1%	$3.5M+4.7%	$3.4M
Selling and marketing	$1.1M-8.1%	$1.2M-2.4%	$1.2M+0.1%	$1.2M
Research and development	$684K+4.1%	$657K+28.6%	$511K+3.9%	$492K
Total operating expenses	$9.4M+2.3%	$9.2M+8.3%	$8.5M+1.1%	$8.4M
Loss from operations	-$267K-292.6%	-$68K+89.7%	-$663K-262.3%	-$183K
Interest expense	-$6K+95.9%	-$145K-4.3%	-$139K-3.0%	-$135K
Interest expense - related party	-$145K	—	—	—
Other income, net	$4K+0.0%	$4K-50.0%	$8K+161.5%	-$13K
Other expense, net	-$151K-7.1%	-$141K-126.5%	$532K+459.5%	-$148K
Net loss	-$418K-100.0%	-$209K-59.5%	-$131K+60.4%	-$331K
Net loss per common share, basic	-$0.05-66.7%	-$0.03-50.0%	-$0.02+50.0%	-$0.04
Net loss per common share, diluted	-$0.05-66.7%	-$0.03-50.0%	-$0.02+50.0%	-$0.04
Weighted-average common shares used to compute net loss per share, basic	$8004389.00+0.0%	$8004389.00+0.0%	$8004389.00+0.0%	$8004389.00
Weighted-average common shares used to compute net loss per share, diluted	$8004389.00+0.0%	$8004389.00+0.0%	$8004389.00+0.0%	$8004389.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.